Clearside BiomedicalCLSDQ 49 Market Cap is $0.65 Mil as of Jul. 06, 2026. GuruFocus rates CLSDQ with a GF Score™ of 49/100 and a GF Value™ of $6.34 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,422 Biotechnology companies, Clearside Biomedical ranks worse than 98.52% on this metric.
Clearside Biomedical's quarterly market cap
declined
from Mar. 2025 ($70.94 Mil) to Jun. 2025 ($62.80 Mil) and
declined
from Jun. 2025 ($62.80 Mil) to Sep. 2025 ($20.78 Mil).
Clearside Biomedical's annual market cap
increased
from Dec. 2022 ($67.92 Mil) to Dec. 2023 ($73.53 Mil) but then
declined
from Dec. 2023 ($73.53 Mil) to Dec. 2024 ($72.75 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Clearside Biomedical's Enterprise Value for Today is $-5.70 Mil.
Clearside Biomedical (OTCPK:CLSDQ) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Clearside Biomedical Market Cap Related Terms
Clearside Biomedical Market Cap Historical Data
* Premium members only.
The historical data trend for Clearside Biomedical's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Clearside Biomedical's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clearside Biomedical Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clearside Biomedical's Market Cap distribution charts can be found below:
* The bar in red indicates where Clearside Biomedical's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Clearside Biomedical's Market Cap for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clearside Biomedical (CLSDQ) has a Market Cap of $0.65 Mil as of Jul. 06, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Clearside Biomedical and its competitors. According to the industry distribution chart, Clearside Biomedical ranks #1401 out of 1422 companies in the Biotechnology industry, placing it in the top 98.5%.
Is Clearside Biomedical's Market Cap too high?
Clearside Biomedical's current Market Cap is $0.65 Mil. The Biotechnology industry median Market Cap is 120.73. Clearside Biomedical's value of $0.65 Mil is 99.5% below this industry median. Based on the distribution chart, Clearside Biomedical ranks #1401 out of 1422 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Clearside Biomedical has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Clearside Biomedical's Market Cap compare to LYRA and EVFM?
According to the Biotechnology industry distribution chart, Clearside Biomedical ranks #1401 out of 1422 companies for Market Cap. This places Clearside Biomedical in the lower half of its industry. The industry median Market Cap is 120.73. Clearside Biomedical's value of $0.65 Mil is 99.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 120.73, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clearside Biomedical's current Market Cap of $0.65 Mil is 99.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Clearside Biomedical and its competitors. For the Biotechnology industry, the median Market Cap is 120.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clearside Biomedical's current Market Cap is $0.65 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clearside Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Clearside Biomedical (CLSDQ) is currently considered Possible Value Trap. The stock's GF Value™ is $6.34, compared to a current price of $0.13 — trading 98% below its estimated fair value. The current Market Cap is $0.65 Mil and 99.5% below the Biotechnology industry median of 120.73. Clearside Biomedical's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Clearside Biomedical (CLSDQ), the current Market Cap is $0.65 Mil as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clearside Biomedical (CLSDQ) Overvalued in 2026?
Based on GuruFocus' analysis, Clearside Biomedical stock appears to be undervalued.
The current stock price of $0.13 is trading 98% below its estimated GF Value™ of $6.34.
GuruFocus considers Clearside Biomedical to be Possible Value Trap.
Key valuation signals for CLSDQ:
Market Cap: $0.65 Mil
GF Value™: $6.34 vs. price of $0.13 (98% below fair value)
Industry Position: 99.5% below the Biotechnology median (#1401 of 1422)
No single metric tells the full story. See the CLSDQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
49GF Score
Get the complete analysis for CLSDQ
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLSDQ has been successfully added to your 
